{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "20298150", "DateCompleted": {"Year": "2010", "Month": "09", "Day": "16"}, "DateRevised": {"Year": "2019", "Month": "09", "Day": "11"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "1873-5592", "JournalIssue": {"Volume": "11", "Issue": "6", "PubDate": {"Year": "2010", "Month": "Jun"}}, "Title": "Current drug targets", "ISOAbbreviation": "Curr Drug Targets"}, "ArticleTitle": "Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.", "Pagination": {"StartPage": "733", "EndPage": "744", "MedlinePgn": "733-44"}, "Abstract": {"AbstractText": ["Terpenoids represent a large and diverse class of naturally occurring compounds found in a variety of fruits, vegetables and medicinal plants. Structurally some of the terpenoids are similar to human hormones. A diet rich in terpenoids is inversely related with the risk of chronic diseases including cancers. Breast and prostate cancers are hormone-related diseases and the second leading cause of female and male cancer mortality. Diterpenoid paclitaxel, and its semi-synthetic analogue docetaxel, have entered clinical use against established breast and prostate cancers. Here we reviewed potential molecular targets and biological properties of natural terpenoids, including monoterpenoids, diterpenoids, triterpenoids and tetraterpenoids, and their applications in treatment of human breast and prostate cancers. These terpenoids are able to inhibit tumor cell proliferation and induce tumor cell death by inhibiting multiple cancer-specific targets including the proteasome, NF-kappaB, and antiapoptotic protein Bcl-2. The efficacy of these terpenoids against breast or prostate cancer cells, as demonstrated in pre-clinical studies support clinical application of these naturally occurring terpenoids in treatment of hormone-related human cancers."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "The Prevention Program, Barbara Ann Karmanos Cancer Institute, and Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA."}], "Identifier": [], "LastName": "Yang", "ForeName": "Huanjie", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Dou", "ForeName": "Q Ping", "Initials": "QP"}], "GrantList": [{"GrantID": "R01 CA120009-04", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "R01 CA120009-04S1", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "1R01CA120009", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "3R01CA120009-04S1", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "R01 CA120009", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "United Arab Emirates", "MedlineTA": "Curr Drug Targets", "NlmUniqueID": "100960531", "ISSNLinking": "1389-4501"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Terpenes"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Prostatic Neoplasms"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Terpenes"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225\u201349.", "ArticleIdList": ["19474385"]}, {"Citation": "Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427\u201333.", "ArticleIdList": ["10688862"]}, {"Citation": "Tharakan R, Lepont P, Singleton D, Kumar R, Khan S. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol Cell Endocrinol. 2008;295:70\u20138.", "ArticleIdList": ["18755239"]}, {"Citation": "Irvin WJ, Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44:2799\u2013805.", "ArticleIdList": ["19008097"]}, {"Citation": "Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869\u201374.", "ArticleIdList": ["PMC58566", "11553815"]}, {"Citation": "Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45(Suppl 1):27\u201340.", "ArticleIdList": ["19775602"]}, {"Citation": "Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009;153:13\u20137.", "ArticleIdList": ["19365520"]}, {"Citation": "Chang C, Saltzman A, Yeh S, et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr. 1995;5:97\u2013125.", "ArticleIdList": ["8845584"]}, {"Citation": "Schaufele F, Carbonell X, Guerbadot M, et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA. 2005;102:9802\u20137.", "ArticleIdList": ["PMC1168953", "15994236"]}, {"Citation": "Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276\u2013308.", "ArticleIdList": ["15082523"]}, {"Citation": "Tamura K, Furihata M, Tsunoda T, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007;67:5117\u201325.", "ArticleIdList": ["17545589"]}, {"Citation": "Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33\u20139.", "ArticleIdList": ["14702632"]}, {"Citation": "Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474\u20138.", "ArticleIdList": ["7522959"]}, {"Citation": "Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors. 2004;22:179\u201384.", "ArticleIdList": ["15518241"]}, {"Citation": "Unni E, Sun S, Nan B, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004;64:7156\u201368.", "ArticleIdList": ["15466214"]}, {"Citation": "Jia L, Shen HC, Wantroba M, et al. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol. 2006;26:7331\u201341.", "ArticleIdList": ["PMC1592894", "16980632"]}, {"Citation": "Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153\u201364.", "ArticleIdList": ["11832206"]}, {"Citation": "Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1\u20134.", "ArticleIdList": ["10929706"]}, {"Citation": "Anichini A, Mortarini R, Sensi M, Zanon M. APAF-1 signaling in human melanoma. Cancer Lett. 2006;238:168\u201379.", "ArticleIdList": ["16095810"]}, {"Citation": "Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305\u20138.", "ArticleIdList": ["9721089"]}, {"Citation": "Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol. 2000;20:929\u201335.", "ArticleIdList": ["PMC85210", "10629050"]}, {"Citation": "Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13\u201321.", "ArticleIdList": ["7923371"]}, {"Citation": "Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. Embo J. 1998;17:7151\u201360.", "ArticleIdList": ["PMC1171061", "9857172"]}, {"Citation": "Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895\u20139.", "ArticleIdList": ["14685250"]}, {"Citation": "Dou QP, Smith DM, Daniel KG, Kazi A. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. Prog Cell Cycle Res. 2003;5:441\u20136.", "ArticleIdList": ["14593738"]}, {"Citation": "Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol. 2004;5:177\u201387.", "ArticleIdList": ["14990998"]}, {"Citation": "Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14:1649\u201357.", "ArticleIdList": ["18347166"]}, {"Citation": "Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2. 4 A resolution. Nature. 1997;386:463\u201371.", "ArticleIdList": ["9087403"]}, {"Citation": "Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000;96:269\u201374.", "ArticleIdList": ["10891461"]}, {"Citation": "Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000;97:3850\u20135.", "ArticleIdList": ["PMC18105", "10725400"]}, {"Citation": "Orlowski RZ, Baldwin AS., Jr NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002;8:385\u20139.", "ArticleIdList": ["12127724"]}, {"Citation": "McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11:164\u201379.", "ArticleIdList": ["18818117"]}, {"Citation": "Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8:33\u201340.", "ArticleIdList": ["PMC2729321", "19116625"]}, {"Citation": "Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458:430\u20137.", "ArticleIdList": ["19325622"]}, {"Citation": "Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res. 2008;42:3\u201318.", "ArticleIdList": ["PMC2965074", "18626576"]}, {"Citation": "Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999;13:270\u201383.", "ArticleIdList": ["PMC316433", "9990852"]}, {"Citation": "Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol. 2006;209:645\u201352.", "ArticleIdList": ["17001676"]}, {"Citation": "Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 2008;27:6228\u201344.", "ArticleIdList": ["18931690"]}, {"Citation": "Lin RJ, Lo WL, Wang YD, Chen CY. A novel cytotoxic monoterpenoid from the leaves of Cinnamomum subavenium. Nat Prod Res. 2008;22:1055\u20139.", "ArticleIdList": ["18780246"]}, {"Citation": "Crowell PL. Monoterpenes in breast cancer chemoprevention. Breast Cancer Res Treat. 1997;46:191\u20137.", "ArticleIdList": ["9478274"]}, {"Citation": "Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN. The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil. Carcinogenesis. 1989;10:781\u20133.", "ArticleIdList": ["2702727"]}, {"Citation": "Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN. Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis. 1988;9:331\u20132.", "ArticleIdList": ["3123086"]}, {"Citation": "Haag JD, Lindstrom MJ, Gould MN. Limonene-induced regression of mammary carcinomas. Cancer Res. 1992;52:4021\u20136.", "ArticleIdList": ["1617679"]}, {"Citation": "Vigushin DM, Poon GK, Boddy A, et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol. 1998;42:111\u20137.", "ArticleIdList": ["9654110"]}, {"Citation": "Sun J. D-Limonene: safety and clinical applications. Altern Med Rev. 2007;12:259\u201364.", "ArticleIdList": ["18072821"]}, {"Citation": "Crowell PL, Siar Ayoubi A, Burke YD. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Adv Exp Med Biol. 1996;401:131\u20136.", "ArticleIdList": ["8886131"]}, {"Citation": "Wilson MJ, Lindgren BR, Sinha AA. The effect of dietary supplementation with limonene or myo-inositol on the induction of neoplasia and matrix metalloproteinase and plasminogen activator activities in accessory sex organs of male Lobund-Wistar rats. Exp Mol Pathol. 2008;85:83\u20139.", "ArticleIdList": ["18675799"]}, {"Citation": "Rabi T, Bishayee A. d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis. J Carcinog. 2009;8:9.", "ArticleIdList": ["PMC2699604", "19465777"]}, {"Citation": "Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 2008;9:2603\u201316.", "ArticleIdList": ["18803448"]}, {"Citation": "Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol. 2007;61:176\u201385.", "ArticleIdList": ["17074501"]}, {"Citation": "Luo XL, Shao Q, Qu HB, Cheng YY. Simple method for determination of five terpenoids from different parts of Tripterygium wilfordii and its preparations by HPLC coupled with evaporative light scattering detection. J Sep Sci. 2007;30:1284\u201391.", "ArticleIdList": ["17623469"]}, {"Citation": "Kupchan SM, Schubert RM. Selective alkylation: a biomimetic reaction of the antileukemic triptolides? Science. 1974;185:791\u20133.", "ArticleIdList": ["4843378"]}, {"Citation": "Li Z, Zhou ZL, Miao ZH, et al. Design and Synthesis of Novel C14-Hydroxyl Substituted Triptolide Derivatives as Potential Selective Antitumor Agents. J Med Chem. 2009", "ArticleIdList": ["19637874"]}, {"Citation": "Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002;8:2666\u201374.", "ArticleIdList": ["12171899"]}, {"Citation": "Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003;2:65\u201372.", "ArticleIdList": ["12533674"]}, {"Citation": "Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem. 1999;274:13451\u20135.", "ArticleIdList": ["10224110"]}, {"Citation": "Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001;20:8009\u201318.", "ArticleIdList": ["11753684"]}, {"Citation": "Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem. 1999;274:13443\u201350.", "ArticleIdList": ["10224109"]}, {"Citation": "Zhu W, Ou Y, Li Y, et al. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol. 2009;75:812\u20139.", "ArticleIdList": ["19158360"]}, {"Citation": "Chang HJ, Kim MH, Baek MK, et al. Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells. Anticancer Res. 2007;27:3411\u20137.", "ArticleIdList": ["17970088"]}, {"Citation": "Vispe S, Devries L, Creancier L, et al. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther. 2009", "ArticleIdList": ["19808979"]}, {"Citation": "Soundararajan R, Sayat R, Robertson GS, Marignani PA. Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biol Ther. 2009:8.", "ArticleIdList": ["19783906"]}, {"Citation": "Leuenroth SJ, Crews CM. Studies on calcium dependence reveal multiple modes of action for triptolide. Chem Biol. 2005;12:1259\u201368.", "ArticleIdList": ["PMC2486259", "16356843"]}, {"Citation": "Kang DW, Lee JY, Oh DH, et al. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exp Mol Med. 2009;41:678\u201385.", "ArticleIdList": ["PMC2753661", "19478552"]}, {"Citation": "Liang M, Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett. 2008;270:337\u201341.", "ArticleIdList": ["18572307"]}, {"Citation": "Liu J, Jiang Z, Xiao J, et al. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine. 2009;16:1006\u201313.", "ArticleIdList": ["19524422"]}, {"Citation": "Zhang R, Zhang PY, Guo J, et al. Effects of triptolide on prostate carcinoma in mouse RM-1 cells. Zhonghua Nan Ke Xue. 2007;13:237\u201341.", "ArticleIdList": ["17393788"]}, {"Citation": "Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005;26:579\u201388.", "ArticleIdList": ["15703811"]}, {"Citation": "Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H, Koeffler HP. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 2003;23:1187\u201393.", "ArticleIdList": ["12964003"]}, {"Citation": "Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 2005;337:224\u201331.", "ArticleIdList": ["16176802"]}, {"Citation": "Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 2001;61:348\u201354.", "ArticleIdList": ["11196185"]}, {"Citation": "Cui Q, Yu JH, Wu JN, et al. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin. 2007;28:1057\u201366.", "ArticleIdList": ["17588343"]}, {"Citation": "Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull. 2007;30:859\u201364.", "ArticleIdList": ["17473426"]}, {"Citation": "Rzeski W, Stepulak A, Szymanski M, et al. Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2006;374:11\u201320.", "ArticleIdList": ["16964520"]}, {"Citation": "Zhou BN. Some progress on the chemistry of natural bioactive terpenoids from Chinese medicinal plants. Mem Inst Oswaldo Cruz. 1991;86(Suppl 2):219\u201326.", "ArticleIdList": ["1842005"]}, {"Citation": "Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese \u201cThunder of God Vine,\u201d is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006;66:4758\u201365.", "ArticleIdList": ["16651429"]}, {"Citation": "Lee JH, Koo TH, Yoon H, et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006;72:1311\u201321.", "ArticleIdList": ["16984800"]}, {"Citation": "Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2007;109:2727\u201335.", "ArticleIdList": ["17110449"]}, {"Citation": "Westerheide SD, Bosman JD, Mbadugha BN, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem. 2004;279:56053\u201360.", "ArticleIdList": ["15509580"]}, {"Citation": "Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol. 2006;33:457\u201365.", "ArticleIdList": ["16890800"]}, {"Citation": "Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10:321\u201330.", "ArticleIdList": ["17010675"]}, {"Citation": "Zhang T, Hamza A, Cao X, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther. 2008;7:162\u201370.", "ArticleIdList": ["18202019"]}, {"Citation": "Hughes D, Guttenplan JB, Marcus CB, Subbaramaiah K, Dannenberg AJ. Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res (Phila Pa) 2008;1:485\u201393.", "ArticleIdList": ["PMC2680610", "19138996"]}, {"Citation": "Yang H, Landis-Piwowar KR, Lu D, et al. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem. 2008;103:234\u201344.", "ArticleIdList": ["17541980"]}, {"Citation": "Tiedemann RE, Schmidt J, Keats JJ, et al. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood. 2009;113:4027\u201337.", "ArticleIdList": ["PMC3952546", "19096011"]}, {"Citation": "Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther. 2005;4:1277\u201385.", "ArticleIdList": ["16093444"]}, {"Citation": "Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5:334\u201346.", "ArticleIdList": ["10956379"]}, {"Citation": "Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 2008;68:7661\u20139.", "ArticleIdList": ["PMC2562581", "18794155"]}, {"Citation": "Ndlovu N, Van Lint C, Van Wesemael K, et al. Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol. 2009;29:5488\u2013504.", "ArticleIdList": ["PMC2756884", "19687301"]}, {"Citation": "Yang H, Shi G, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from \u201cIndian winter cherry\u201d. Mol Pharmacol. 2007;71:426\u201337.", "ArticleIdList": ["17093135"]}, {"Citation": "Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007;67:246\u201353.", "ArticleIdList": ["17185378"]}, {"Citation": "Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol. 1995;49:57\u201368.", "ArticleIdList": ["8847885"]}, {"Citation": "Zhang GP, Lu YY, Lv JC, Ou HJ. Effect of ursolic acid on caspase-3 and PARP expression of human MCF-7 cells. Zhongguo Zhong Yao Za Zhi. 2006;31:141\u20134.", "ArticleIdList": ["16570804"]}, {"Citation": "Kassi E, Sourlingas TG, Spiliotaki M, et al. Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. Cancer Invest. 2009;27:723\u201333.", "ArticleIdList": ["19440893"]}, {"Citation": "Nangia-Makker P, Tait L, Shekhar MP, et al. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer. 2007;121:884\u201394.", "ArticleIdList": ["PMC3613994", "17437270"]}, {"Citation": "Zhang YX, Kong CZ, Wang HQ, Wang LH, Xu CL, Sun YH. Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. Biochimie. 2009;91:1173\u20139.", "ArticleIdList": ["19545597"]}, {"Citation": "Tapiero H, Townsend DM, Tew KD. The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother. 2004;58:100\u201310.", "ArticleIdList": ["PMC6361147", "14992791"]}, {"Citation": "Sato R, Helzlsouer KJ, Alberg AJ, Hoffman SC, Norkus EP, Comstock GW. Prospective study of carotenoids, tocopherols, and retinoid concentrations and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:451\u20137.", "ArticleIdList": ["12010859"]}, {"Citation": "Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol. 2008;6:29\u201336.", "ArticleIdList": ["18302908"]}, {"Citation": "Wu K, Erdman JW, Jr, Schwartz SJ, et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:260\u20139.", "ArticleIdList": ["14973107"]}, {"Citation": "Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: A systematic review and meta-analysis of randomized controlled trials. Int J Cancer. 2009", "ArticleIdList": ["19876916"]}, {"Citation": "Chalabi N, Satih S, Delort L, Bignon YJ, Bernard-Gallon DJ. Expression profiling by whole-genome microarray hybridization reveals differential gene expression in breast cancer cell lines after lycopene exposure. Biochim Biophys Acta. 2007;1769:124\u201330.", "ArticleIdList": ["17321611"]}, {"Citation": "Li Z, Wang Y, Mo B. The effects of carotenoids on the proliferation of human breast cancer cell and gene expression of bcl-2. Zhonghua Yu Fang Yi Xue Za Zhi. 2002;36:254\u20137.", "ArticleIdList": ["12411207"]}, {"Citation": "Molnar J, Gyemant N, Mucsi I, et al. Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids. In Vivo. 2004;18:237\u201344.", "ArticleIdList": ["15113052"]}, {"Citation": "Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2007;59:1\u20137.", "ArticleIdList": ["17927495"]}, {"Citation": "Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW., Jr Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res. 2007;67:836\u201343.", "ArticleIdList": ["17213256"]}, {"Citation": "Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2001;10:861\u20138.", "ArticleIdList": ["11489752"]}, {"Citation": "Cui Y, Lu Z, Bai L, Shi Z, Zhao WE, Zhao B. beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells. Eur J Cancer. 2007;43:2590\u2013601.", "ArticleIdList": ["17911009"]}]}], "History": [{"Year": "2009", "Month": "12", "Day": "13"}, {"Year": "2010", "Month": "1", "Day": "22"}, {"Year": "2010", "Month": "3", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "3", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "9", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2012", "Month": "3", "Day": "17"}], "PublicationStatus": "ppublish", "ArticleIdList": ["20298150", "NIHMS362036", "PMC3306610", "10.2174/138945010791170842", "BSP/CDT/E-Pub/00071"]}}], "PubmedBookArticle": []}